Literature DB >> 27230511

The relevance of Tim-3 polymorphisms and F protein to the outcomes of HCV infection.

J P Pei1, L F Jiang2, X W Ji1, W Xiao3, X Z Deng4,5, Z X Zhou6, D Y Zhu7, W L Ding8, J H Zhang9, C J Wang9, K Jing10.   

Abstract

Hepatitis C virus (HCV) is one of the major causes of liver inflammation. The aim of this study was to investigate the associations of T-cell immunoglobulin and mucin domain-3 (Tim-3) polymorphisms and the alternate reading frame protein (F protein) with the outcomes of HCV infection. Three single-nucleotide polymorphisms (SNPs; rs10053538, rs12186731, and rs13170556) of Tim-3 were genotyped in this study, which included 203 healthy controls, 558 hepatitis C anti-F-positive patients, and 163 hepatitis C anti-F-negative patients. The results revealed that the rs12186731 CT and rs13170556 TC and CC genotypes were significantly less frequent in the anti-F-positive patients [odds ratio (OR) = 0.54, 95 % confidence interval (CI) = 0.35-0.83, p = 0.005; OR = 0.26, 95 % CI = 0.18-0.39, p < 0.001; and OR = 0.19, 95 % CI = 0.10-0.35, p < 0.001, respectively), and the rs13170556 TC genotype was more frequent in the chronic HCV (CHC) patients (OR = 1.70, 95 % CI = 1.20-2.40, p = 0.002). The combined analysis of the rs12186731 CT and rs13170556 TC/CC genotypes revealed a locus-dosage protective effect in the anti-F-positive patients (OR = 0.22, 95 % CI = 0.14-0.33, p trend < 0.001). Stratified analyses revealed that the frequencies of the rs12186731 (CT + TT) genotypes were significantly lower in the older (OR = 0.31, 95 % CI = 0.15-0.65, p = 0.002) and female (OR = 0.30, 95 % CI = 0.17-0.52, p < 0.001) subgroups, and rs13170556 (TC + CC) genotypes exhibited the same effect in all subgroups (all p < 0.001) in the anti-F antibody generations. Moreover, the rs13170556 (TC + CC) genotypes were significantly more frequent in the younger (OR = 1.86, 95 % CI = 1.18-2.94, p = 0.007) and female (OR = 2.38, 95 % CI = 1.48-3.83, p < 0.001) subgroups of CHC patients. These findings suggest that the rs12186731 CT and rs13170556 TC/CC genotypes of Tim-3 provide potential protective effects with the F protein in the outcomes of HCV infection and that these effects are related to sex and age.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27230511     DOI: 10.1007/s10096-016-2676-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  41 in total

1.  Blockade of Tim-3 signaling restores the virus-specific CD8⁺ T-cell response in patients with chronic hepatitis B.

Authors:  Wei Wu; Yu Shi; Shuping Li; Yun Zhang; Yanning Liu; Yihua Wu; Zhi Chen
Journal:  Eur J Immunol       Date:  2012-05       Impact factor: 5.532

2.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  Alternate translation occurs within the core coding region of the hepatitis C viral genome.

Authors:  Agoritsa Varaklioti; Niki Vassilaki; Urania Georgopoulou; Penelope Mavromara
Journal:  J Biol Chem       Date:  2002-03-07       Impact factor: 5.157

4.  Characterization of humoral and cell-mediated immune responses directed against hepatitis C virus F protein in subjects co-infected with hepatitis C virus and HIV-1.

Authors:  Myriam Troesch; Emilie Jalbert; Sophie Canobio; M Rachid Boulassel; Jean-Pierre Routy; Nicole F Bernard; Julie Bruneau; Normand Lapointe; Marc Boucher; Hugo Soudeyns
Journal:  AIDS       Date:  2005-05-20       Impact factor: 4.177

5.  Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3.

Authors:  Lucy Golden-Mason; Christine E Waasdorp Hurtado; Linling Cheng; Hugo R Rosen
Journal:  Clin Immunol       Date:  2015-03-19       Impact factor: 3.969

6.  High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma.

Authors:  G Dalagiorgou; N Vassilaki; P Foka; A Boumlic; A Kakkanas; E Kochlios; S Khalili; E Aslanoglou; S Veletza; G Orfanoudakis; D Vassilopoulos; S J Hadziyannis; J Koskinas; P Mavromara
Journal:  J Gen Virol       Date:  2011-02-09       Impact factor: 3.891

Review 7.  The bitter side of sweet: the role of Galectin-9 in immunopathogenesis of viral infections.

Authors:  Shahzma Merani; Wenna Chen; Shokrollah Elahi
Journal:  Rev Med Virol       Date:  2015-03-11       Impact factor: 6.989

8.  Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity.

Authors:  P Simmonds; F McOmish; P L Yap; S W Chan; C K Lin; G Dusheiko; A A Saeed; E C Holmes
Journal:  J Gen Virol       Date:  1993-04       Impact factor: 3.891

9.  Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection.

Authors:  Christine Bain; Peggy Parroche; Jean Pierre Lavergne; Blandine Duverger; Claude Vieux; Valérie Dubois; Florence Komurian-Pradel; Christian Trépo; Lucette Gebuhrer; Glaucia Paranhos-Baccala; François Penin; Geneviève Inchauspé
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

View more
  1 in total

Review 1.  Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.

Authors:  Hyosun Cho; Hyojeung Kang; Hwan Hee Lee; Chang Wook Kim
Journal:  Int J Mol Sci       Date:  2017-07-13       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.